1. Home
  2. STKE vs CUE Comparison

STKE vs CUE Comparison

Compare STKE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc.

N/A

Current Price

$2.20

Market Cap

61.4M

Sector

N/A

ML Signal

N/A

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.30

Market Cap

49.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
CUE
Founded
2002
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.4M
49.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
STKE
CUE
Price
$2.20
$0.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.00
AVG Volume (30 Days)
320.0K
1.9M
Earning Date
01-06-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,456,249.00
$7,100,000.00
Revenue This Year
$45.67
N/A
Revenue Next Year
N/A
$25.00
P/E Ratio
N/A
N/A
Revenue Growth
37.18
N/A
52 Week Low
$1.50
$0.23
52 Week High
$34.32
$1.54

Technical Indicators

Market Signals
Indicator
STKE
CUE
Relative Strength Index (RSI) N/A 38.47
Support Level N/A $0.27
Resistance Level N/A $0.37
Average True Range (ATR) 0.00 0.05
MACD 0.00 0.01
Stochastic Oscillator 0.00 23.35

Price Performance

Historical Comparison
STKE
CUE

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: